COMMUNIQUÉS West-GlobeNewswire

HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune
13/02/2026
HCW Biologics receiving cash fee and co-founder shares in Trimmune valued at $7.0 million Trimmune will hold exclusive worldwide license for rights to high potential preclinical molecule created with HCW Biologics’ TRBC [...]
Conavi Medical Highlights Peer-Reviewed Publication Demonstrating Advantages of Hybrid IVUS-OCT Imaging
13/02/2026
- New Academic Data Supports Clinical and Commercial Value of Hybrid Imaging Platform- TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (“Conavi” or the “Company”), a leader in hybrid intravascular [...]
Medicenna Announces Changes to Board Composition
13/02/2026
TORONTO and HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]
Opus Genetics Announces $25 Million Private Placement
13/02/2026
RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc . (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore [...]
Sienna Announces February Dividend
13/02/2026
MARKHAM, Ontario, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
Lyv Launches in the UK to Support The 500,000 Patients Going Private for Weight Loss Treatment
13/02/2026
Online pharmacy enters booming weight loss market with end to end patient care model as private prescriptions surge LONDON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- A UK online pharmacy has entered the rapidly expanding weight [...]
Nxera Pharma Proposes Changes to its Board of Directors
13/02/2026
Mr. Takeo Morooka nominated for appointment as new External Director Ms. Miwa Seki and Mr. Noriaki Nagai to retire from the Board of Directors Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“ [...]
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025
13/02/2026
Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the fourth quarter and [...]
EssilorLuxottica announces the launch of a share buyback program
13/02/2026
EssilorLuxottica announces the launch of a share buyback program Paris, France (13 February 2026 – 8:00am) – EssilorLuxottica announces the launch of a share buyback program, reflecting the Group’s confidence in its [...]
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
13/02/2026
In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended 1 Results favored Vanrafia across multiple timepoints, measures [...]
EssilorLuxottica annonce le lancement d’un programme de rachat d’actions
13/02/2026
EssilorLuxottica annonce le lancement d’un programme de rachat d’actions Paris, France (13 février 2026 – 8h00) – EssilorLuxottica annonce le lancement d’un programme de rachat d’actions qui traduit la confiance du [...]
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
13/02/2026
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of 28,600,000 shares of the [...]
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
13/02/2026
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Tilray élargit son accès aux produits pharmaceutiques au Royaume-Uni grâce à un accord stratégique avec Smartway Pharmaceuticals
13/02/2026
L’accord avec CC Pharma renforce la croissance de Tilray au Royaume-Uni, consolidant sa distribution auprès des pharmacies et des hôpitaux NEW YORK et LONDRES, 13 févr. 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, la [...]
InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
13/02/2026
BEIJING, Feb. 12, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first [...]
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
13/02/2026
US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs US$40 Million NIAID Funding Award Supports VXV-01 Development Through Phase 1 LIKMEZ® (ATI-1501) Commercial Momentum with Increased U.S. [...]
Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
13/02/2026
Approval will broaden the NARCAN ® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE [...]
Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
12/02/2026
2025 total revenue of $673 million, Crysvita ® revenue of $481 million and Dojolvi ® revenue of $96 million 2026 total revenue from current products expected to be between $730 million to $760 million Initiated a [...]
Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2025 Results Report
12/02/2026
NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period and full year ended [...]

Pages